179 related articles for article (PubMed ID: 37115298)
1. Utility of the frailty score for predicting prognosis and individualizing treatment intensity in elderly patients with diffuse large B cell lymphoma.
Yagi Y; Kanemasa Y; Sasaki Y; Goto S; Yamamura Y; Ishimine K; Hayashi Y; Mino M; Ohigashi A; Morita Y; Tamura T; Nakamura S; Okuya T; Shimoyama T
Ann Hematol; 2023 Jun; 102(6):1485-1500. PubMed ID: 37115298
[TBL] [Abstract][Full Text] [Related]
2. A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL.
Isaksen KT; Mastroianni MA; Rinde M; Rusten LS; Barzenje DA; Ramslien LF; Slaaen M; Jerm MB; Smeland EB; Rostoft S; Liestøl K; Brodtkorb M; Holte H
Blood Adv; 2021 Nov; 5(22):4771-4782. PubMed ID: 34543384
[TBL] [Abstract][Full Text] [Related]
3. Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma.
Miura K; Takahashi H; Nakagawa M; Hamada T; Uchino Y; Iizuka K; Ohtake S; Iriyama N; Hatta Y; Nakamura H
Expert Rev Anticancer Ther; 2022 Jun; 22(6):583-595. PubMed ID: 35472312
[TBL] [Abstract][Full Text] [Related]
4. Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age.
Eyre TA; Martinez-Calle N; Hildyard C; Eyre DW; Plaschkes H; Griffith J; Wolf J; Fields P; Gunawan A; Oliver R; Djebbari F; Booth S; McMillan A; Fox CP; Bishton MJ; Collins GP; Hatton CSR
J Intern Med; 2019 Jun; 285(6):681-692. PubMed ID: 30811713
[TBL] [Abstract][Full Text] [Related]
5. Electronic FRAIL score as a predictor of treatment outcomes in older patients with diffuse large B-cell lymphoma.
Zhang J; Disperati P; Elinder-Camburn A; Merriman E; Leitch S; Chan H
J Geriatr Oncol; 2022 May; 13(4):505-510. PubMed ID: 34906444
[TBL] [Abstract][Full Text] [Related]
6. A Host-Dependent Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma.
Miura K; Konishi J; Miyake T; Makita M; Hojo A; Masaki Y; Uno M; Ozaki J; Yoshida C; Niiya D; Kitazume K; Maeda Y; Takizawa J; Sakai R; Yano T; Yamamoto K; Sunami K; Hiramatsu Y; Aoyama K; Tsujimura H; Murakami J; Hatta Y; Kanno M
Oncologist; 2017 May; 22(5):554-560. PubMed ID: 28408622
[TBL] [Abstract][Full Text] [Related]
7. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma.
Chihara D; Westin JR; Oki Y; Ahmed MA; Do B; Fayad LE; Hagemeister FB; Romaguera JE; Fanale MA; Lee HJ; Turturro F; Samaniego F; Neelapu SS; Rodriguez MA; Fowler NH; Wang M; Davis RE; Nastoupil LJ
Cancer; 2016 Oct; 122(20):3145-3151. PubMed ID: 27351173
[TBL] [Abstract][Full Text] [Related]
8. Adjusted Chemotherapy According to Frailty Status in Elderly Patients With Diffuse Large B-Cell Lymphoma: Experience From a Single Referral Center in Mexico City.
Lastra-German IK; Navarrete-Reyes AP; Mejía-Domínguez NR; Agreda-Vásquez GP
Clin Lymphoma Myeloma Leuk; 2019 Feb; 19(2):e98-e106. PubMed ID: 30545670
[TBL] [Abstract][Full Text] [Related]
9. An evaluation based on relative treatment intensity in older patients treated with reduced-dose R-THP-COP therapy for diffuse large B-cell lymphoma: A multicenter retrospective cohort study.
Hiroi T; Hosoi H; Kuriyama K; Murata S; Morimoto M; Mushino T; Nishikawa A; Tamura S; Sonoki T
J Geriatr Oncol; 2023 Jan; 14(1):101396. PubMed ID: 36328877
[TBL] [Abstract][Full Text] [Related]
10. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
[No Abstract] [Full Text] [Related]
11. R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma.
Laribi K; Denizon N; Bolle D; Truong C; Besançon A; Sandrini J; Anghel A; Farhi J; Ghnaya H; Baugier de Materre A
Ann Hematol; 2016 Oct; 95(10):1705-14. PubMed ID: 27485454
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.
Merli F; Luminari S; Rossi G; Mammi C; Marcheselli L; Tucci A; Ilariucci F; Chiappella A; Musso M; Di Rocco A; Stelitano C; Alvarez I; Baldini L; Mazza P; Salvi F; Arcari A; Fragasso A; Gobbi PG; Liberati AM; Federico M
Leuk Lymphoma; 2012 Apr; 53(4):581-8. PubMed ID: 21895543
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Geriatric Assessment (CGA): A Simple Tool for Guiding the Treatment of Older Adults with Diffuse Large B-Cell Lymphoma in China.
Bai JF; Han HX; Feng R; Li JT; Wang T; Zhang CL; Liu H
Oncologist; 2020 Aug; 25(8):e1202-e1208. PubMed ID: 32436258
[TBL] [Abstract][Full Text] [Related]
14. Impact of comorbidity and relative dose intensity on outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP.
Yamamoto M; Suzuki I; Saitou K; Tsumanuma R; Okuyama S; Kumagai H; Omoto E; Satoh S; Tajima K
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2995-3002. PubMed ID: 32524293
[TBL] [Abstract][Full Text] [Related]
15. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
16. Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma.
Utsu Y; Takaishi K; Inagaki S; Arai H; Yuasa H; Masuda S; Matsuura Y; Aotsuka N; Wakita H
Ann Hematol; 2016 Jan; 95(1):41-47. PubMed ID: 26435364
[TBL] [Abstract][Full Text] [Related]
17. Frontline treatment of diffuse large B-cell lymphoma in elderly: a systematic review of clinical trials in post-rituximab era.
Beygi S; Sadashiv S; Reilly JB; Khan C; Lister J
Leuk Lymphoma; 2018 Dec; 59(12):2847-2861. PubMed ID: 29616868
[TBL] [Abstract][Full Text] [Related]
18. Considerations for the Treatment of Diffuse Large B Cell Lymphoma in the Elderly.
Khan Y; Brem EA
Curr Hematol Malig Rep; 2019 Aug; 14(4):228-238. PubMed ID: 31228094
[TBL] [Abstract][Full Text] [Related]
19. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of six versus eight cycles of standard regimen in patients with diffuse large B-cell lymphoma: propensity score-matching analysis.
Oiwa K; Fujita K; Lee S; Morishita T; Tsukasaki H; Negoro E; Hara T; Tsurumi H; Ueda T; Yamauchi T
ESMO Open; 2021 Aug; 6(4):100210. PubMed ID: 34271313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
